Views & Analysis The PPRS medicines pricing scheme: is it working for both si... The PPRS has now reached the half-way stage - a look at the stats so far.
Views & Analysis Flexible models for better access Which initiatives are the most likely to bring life-changing therapies to patients?
Views & Analysis Sitting uncomfortably? The UK’s PPRS and statutory schemes Do the PPRS and the statutory scheme run effectively in parallel?
Views & Analysis Access to cancer drugs: planning for every outcome New UK oncology drug assessment procedures examined.
Views & Analysis Patient Access Schemes: a look behind the scenes Leela Barham takes a look behind the schemes for patient access in England and puts the case for a review to bring them up to date, in the light of changes since they began in 2009.
Oncology CAR-T therapies: Faster, better, cheaper In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
